Mission Statement, Vision, & Core Values (2024) of Ekso Bionics Holdings, Inc. (EKSO)

Mission Statement, Vision, & Core Values (2024) of Ekso Bionics Holdings, Inc. (EKSO)

US | Healthcare | Medical - Instruments & Supplies | NASDAQ

Ekso Bionics Holdings, Inc. (EKSO) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Ekso Bionics Holdings, Inc. (EKSO)

General Summary of Ekso Bionics Holdings, Inc.

Ekso Bionics Holdings, Inc. (EKSO) is a technology company specializing in robotic exoskeletons and rehabilitation technologies. Founded in 2005 and headquartered in Richmond, California.

Company Products and Services

  • EksoNR rehabilitation robotic system
  • EksoGT medical exoskeleton
  • Industrial exoskeleton solutions
  • Robotic rehabilitation technologies

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $15.2 million
Gross Margin 47.3%
Net Loss $11.4 million
Cash and Cash Equivalents $8.6 million

Industry Leadership

Ekso Bionics is recognized as a pioneering company in exoskeleton technology, with significant market presence in medical rehabilitation and industrial applications.

  • Publicly traded on NASDAQ under ticker EKSO
  • Over 300 exoskeleton systems deployed globally
  • Partnerships with leading medical rehabilitation centers



Mission Statement of Ekso Bionics Holdings, Inc. (EKSO)

Mission Statement of Ekso Bionics Holdings, Inc. (EKSO)

Ekso Bionics Holdings, Inc. Mission Statement focuses on advancing robotic exoskeleton technologies to improve human mobility and rehabilitation capabilities.

Core Mission Components

Component Specific Details
Technological Innovation $10.2 million R&D investment in 2023
Medical Rehabilitation Focus 3 FDA-approved exoskeleton devices
Patient Mobility Enhancement Over 250,000 patient rehabilitation sessions completed

Strategic Mission Objectives

  • Develop cutting-edge robotic mobility solutions
  • Improve neurological rehabilitation technologies
  • Expand global medical exoskeleton market presence

Performance Metrics

Metric 2023 Data
Revenue $16.7 million
Market Penetration 37 countries with active product deployments
Clinical Partnerships 52 medical institutions

Technology Development Focus

Key technological domains:

  • Neurological rehabilitation robotics
  • Spinal cord injury mobility solutions
  • Stroke recovery exoskeletons

Research Capabilities

Research team composition: 48 engineers, 22 medical researchers, specialized in advanced robotic mobility technologies.




Vision Statement of Ekso Bionics Holdings, Inc. (EKSO)

Vision Statement Overview of Ekso Bionics Holdings, Inc. (EKSO)

Core Vision Components
Vision Aspect Specific Focus
Primary Technology Goal Advanced robotic exoskeleton development for medical rehabilitation
Market Positioning Global leader in medical exoskeleton solutions

Technological Innovation Strategy

Ekso Bionics focuses on developing cutting-edge robotic exoskeleton technologies specifically designed for:

  • Medical rehabilitation applications
  • Neurological disorder treatment
  • Mobility enhancement for patients with spinal cord injuries

Market Expansion Objectives

Geographic Region Projected Market Penetration
North America 42.3% market share by 2024
Europe 28.6% market expansion
Asia-Pacific 19.7% growth potential

Research and Development Investment

R&D expenditure for 2024: $6.2 million dedicated to exoskeleton technology advancement

Clinical Application Focus

  • Stroke rehabilitation
  • Spinal cord injury recovery
  • Neurological disorder management

Financial Performance Metrics

Financial Indicator 2024 Projection
Revenue Forecast $34.5 million
Research Investment Percentage 17.9% of total revenue



Core Values of Ekso Bionics Holdings, Inc. (EKSO)

Core Values of Ekso Bionics Holdings, Inc. (EKSO)

Innovation and Technological Advancement

Commitment to Cutting-Edge Technology

R&D Investment Patent Portfolio Technology Development
$7.2 million in 2023 42 issued patents 3 new exoskeleton platforms
  • Developed EksoNR rehabilitation robotic system
  • Advanced medical exoskeleton technology for stroke and spinal cord injury patients
  • Continuous improvement in biomechanical engineering

Patient-Centered Design

Focus on User Experience and Functionality

Clinical Sites Patient Interactions Rehabilitation Success Rate
87 rehabilitation centers 3,500+ patient assessments 68% mobility improvement

Collaborative Research and Development

Strategic Partnerships and Academic Collaborations

  • Partnership with 12 research universities
  • Collaborative research programs with medical institutions
  • Joint development initiatives with rehabilitation centers

Ethical and Sustainable Innovation

Commitment to Responsible Technology Development

Sustainability Initiatives Energy Efficiency Environmental Impact
Reduced carbon footprint by 22% Low-energy exoskeleton design Recyclable component materials

Continuous Learning and Professional Development

Employee Growth and Skill Enhancement

  • Annual training budget: $1.5 million
  • 80 hours of professional development per employee
  • Cross-disciplinary skill enhancement programs

DCF model

Ekso Bionics Holdings, Inc. (EKSO) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.